Migalastat Hydrochloride 123 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 123 mg

Reference Brands: Galafold (USA/EU)

Category: Orphan Drugs

Migalastat is an orally administered small molecule that acts as a “pharmacological chaperone” by binding and stabilizing the enzyme α-galactosidase A (α-Gal A) in patients with certain amenable mutations, thereby helping to clear the substrate accumulation seen in Fabry disease.

Product Description:

Migalastat is a pharmacological chaperone, and its mechanism is unusual. In Fabry disease, mutations in the gene for alpha-galactosidase A often produce an enzyme that folds incorrectly and is destroyed by the cell's quality control before it reaches the lysosome — the protein is not absent, just misfolded. Migalastat binds the enzyme's active site and stabilises the folded shape, so it survives trafficking to the lysosome, where the acidic environment releases it and it works.

It is used for Fabry disease in patients aged twelve and over who have an amenable mutation — and that qualifier is central, because the chaperone only helps mutations that produce a rescuable protein. Roughly a third to a half of Fabry mutations are amenable, determined by a validated in vitro test, and patients without one gain nothing. For those who qualify it is an oral capsule taken every other day, against the fortnightly intravenous infusions that enzyme replacement therapy requires. Headache is the commonest adverse effect.

Sourcing notes. Originator product, on patent, no generic. Access depends on genotype testing and on a published amenability table, so the destination market needs that testing. Supply is through authorised distribution; the competition is enzyme replacement therapy, not another oral agent.